Lung Cancer Trials Ask AI to find trials
TerminatedNot applicableNCT02121899
Official study title

Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)

Study summary

This registry is intended to measure the effect of myPlan Lung Cancer™ test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC. The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006). This registry is specific to Oncologists (ONC006).

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 5, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Myriad Genetic Laboratories, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Myriad Genetic Laboratories, Inc.
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Diagnosis of early stage non-small cell lung adenocarcinoma
  • Sub-population staging (IA, IB or IIA) as judged by the standard of practice at the investigational site
  • Resection of tumor within previous 2 months of enrollment
  • ECOG performance of 0-2
  • A minimum life expectancy of six months
Reasons someone may not be able to joinExclusion criteria
  • Previous myPlan Lung Cancer test performed
  • Pre-operative radiation or chemotherapy for NSCLC
  • Post-operative radiation or chemotherapy for NSCLC
  • Enrollment in a separate clinical trial restricting treatment options
  • Unable to provide informed consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Study locationOrlando, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 5, 2017. Always confirm current availability with the study team.

View original record ↗